Keqian Biology(SH:688526) Zheng Quan Zhi Xing·2025-08-27 11:57Financial Performance - The company reported a total revenue of 487 million yuan for the first half of 2025, representing a year-on-year increase of 21.67% [1] - The net profit attributable to shareholders reached 220 million yuan, up 44.09% year-on-year [1] - In Q2 2025, the revenue was 242 million yuan, showing a 23.79% increase compared to the same quarter last year [1] - The net profit for Q2 was 112 million yuan, reflecting a significant year-on-year growth of 70.78% [1] - The gross margin improved by 6.4% to 67.28%, while the net margin increased by 18.39% to 45.0% [1] Cost Management - Total selling, administrative, and financial expenses amounted to 49.39 million yuan, accounting for 10.14% of revenue, which is a decrease of 20.77% year-on-year [1] - The company’s earnings per share (EPS) increased by 42.42% to 0.47 yuan [1] Asset and Liability Management - The company’s cash assets are reported to be very healthy, indicating strong solvency [4] - Significant changes in financial items include a 77.66% increase in accounts receivable financing due to an increase in bank acceptance bills [3] - Prepayments increased by 117.37% due to higher advance feed payments [3] Investment and Return Metrics - The company's return on invested capital (ROIC) was reported at 7.91%, indicating average investment returns [4] - Analysts expect the company to achieve a revenue of 456 million yuan in 2025, with an average EPS forecast of 0.98 yuan [4] Shareholder Information - The largest fund holding in the company is the Qianhai Kaiyuan Xianghe Bond A fund, which holds 307,500 shares and has recently entered the top ten holdings [5] - The fund has a current scale of 1.667 billion yuan and has seen a 10.11% increase over the past year [5]